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Vascular endothelial growth factor (VEGF) has been
implicated in the pathologic angiogenesis observed in
psoriasis andother chronic inflammatory skin diseases that
are characterized by enhanced expression of VEGF by
epidermal keratinocytes and of VEGF receptors by
tortuous microvessels in the upper dermis. To investigate
the functional importance of chronic VEGF overexpres-
sion in vivo, we used a keratin 14 promoter expression
cassette containing the gene for murine VEGF164 to select-
ively target VEGF expression to basal epidermal ker-
atinocytes in transgenic mice. These mice demonstrated
an increased density of tortuous cutaneous blood capil-
laries with elevated expression levels of the high affinity
VEGF receptors, VEGFR-1 and VEGFR-2, most promin-
entlyduringtheneonatalperiod. Incontrast,noabnormal-
ities of lymphatic vessels were detected. In addition, the
number of mast cells in the upper dermis was significantly
Common chronic inflammatory diseases such as psoriasisand rheumatoid arthritis are characterized by leukocyteinfiltration, angiogenesis, and vascular remodelling lead-ing to enhanced tortuosity of blood microvessels (Ryan,1980; Braverman and Sibley, 1982; Braverman and
Keh-Yen, 1986; Bull et al, 1992; Fava et al, 1994; Koch et al, 1994).
Previously, we have demonstrated increased expression of vascular
endothelial growth factor (VEGF; also known as vascular permeability
factor) by epidermal keratinocytes, and of the two high-affinity VEGF
receptors, VEGFR-1 (Flt-1) (deVries et al, 1992) and VEGFR-2
(KDR) (Terman et al, 1992) by dermal microvessels in psoriasis, contact
dermatitis, and several chronic inflammatory bullous skin diseases with
enhanced angiogenesis (Detmar et al, 1994; Brown et al, 1995a, b).
Moreover, enhanced VEGF and VEGF receptor expression was a
characteristic feature of lesional skin in a recently described mouse
model for chronic, psoriasiform skin inflammation (Scho¨n et al, 1997);
however, it has remained unclear whether keratinocyte-secreted VEGF,
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increased in transgenic skin. Intravital fluorescencemicro-
scopy revealed highly increased leukocyte rolling and
adhesion inpostcapillary skinvenules thatwereboth inhib-
ited after injection of blocking antibodies against E- and
P-selectin. Combined blocking antibodies against inter-
cellular adhesion molecule-1 and lymphocyte function-
associated antigen-1 were without effect, whereas an anti-
vascular cell adhesion molecule-1/VLA-4 antibody com-
bination almost completely normalized the enhanced
leukocyte adhesion in transgenic mice. This study reveals
VEGF as a growth factor specific for blood vessels, but not
lymphatic vessels, and demonstrates that chronic ortho-
topic overexpression of VEGF in the epidermis is sufficient
to induce cardinal features of chronic skin inflammation,
providing a molecular link between angiogenesis, mast
cell accumulation, and leukocyte recruitment to sites of
inflammation. Key words: angiogenesis/endothelium/VPF/
mast cells. J Invest Dermatol 111:1–6, 1998
predominantly the VEGF165 and VEGF121 splice variants (Ballaun et al,
1995; Detmar et al, 1995, 1997), can penetrate the epidermal–dermal
basement membrane to reach its target cells on dermal microvessels, and
whether VEGF itself might be involved in the observed upregulation of
its receptors.
Previously, we have shown that keratinocyte-derived VEGF is a
potent mitogen for human dermal microvascular endothelial cells that
express both VEGFR-1 and VEGFR-2 in vitro (Detmar et al, 1995).
VEGF also enhanced endothelial cell migration through upregulation
of the αvβ3 integrin (Senger et al, 1996) that has been found upregulated
on skin microvessels in psoriasis (Creamer and Barker, 1995), and of
the α1β1, and α2β1 integrins (Senger et al, 1997). These findings
suggested a major role of VEGF in the mediation of the vascular
remodelling characteristic of chronic skin inflammation; however, the
precise biologic importance of VEGF for this process is still unknown
because VEGF deficiency is lethal during early embryonic development
(Carmeliet et al, 1996; Ferrara et al, 1996), preventing evaluation of
skin angiogenesis in VEGF deficient mice. Moreover, whereas injection
of VEGF into the skin leads to acutely increased microvascular
permeability to plasma macromolecules (Senger et al, 1990), chronic
topical delivery of VEGF to the skin could not be achieved.
To study the specific biologic consequences of chronic VEGF
overexpression in the skin, we generated transgenic mice, using a
transgene vector in which the coding sequence of murine VEGF164
was cloned into a human keratin 14 promoter expression cassette. The
human keratin 14 expression cassette has previously been shown to
selectively target transgene expression to basal keratinocytes of the skin
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Figure 1. Schematic representation of the K14-VEGF transgene
construct. A 980 bp murine VEGF164 BamHI cDNA fragment, coding for
the 164-amino acid VEGF splice variant, was ligated to the BamHI restriction
site of the keratin 14 promoter expression cassette.
(Vassar et al, 1989; Vassar and Fuchs, 1991; Turksen et al, 1992; Guo
et al, 1993), providing thereby an orthotopical model to assess the
effects of epidermis-derived VEGF on skin angiogenesis in vivo. In this
study, we found that VEGF transgenic mice were characterized by an
increased density of tortuous cutaneous blood capillaries with elevated
expression levels of VEGFR-1 and VEGFR-2, most prominently
during the neonatal period, whereas no abnormalities of lymphatic
vessels were detected, establishing VEGF as a blood vessel-specific
skin angiogenesis factor. Using intravital fluorescence microscopy, we
detected dramatically increased leukocyte rolling and adhesion in
postcapillary skin venules that were both completely inhibited after
injection of blocking antibodies against E- and P-selectin. In addition,
an anti-vascular cell adhesion molecule-1 (VCAM-1)/VLA-4 antibody
combination almost completely normalized the enhanced leukocyte
adhesion in transgenic mice. Thus, chronic orthotopic overexpression
of VEGF in the epidermis was sufficient to induce cardinal pathologic
features of psoriasis, providing further evidence for the role of VEGF
as a major skin angiogenesis factor in chronic inflammation and as a
novel molecular link between angiogenesis and leukocyte recruitment
to sites of inflammation.
MATERIALS AND METHODS
Generation of mice A 980 bp murine VEGF164 cDNA (GenBank accession
number M95200) was ligated into the BamHI restriction site of the keratin 14
expression cassette (Vassar et al, 1989; kindly provided by Dr. Elaine Fuchs,
University of Chicago; Fig 1), and a KpnI-HindIII fragment was purified and
injected into FVB/N mouse zygotes. The injected embryos were transplanted
into the uterus of pseudo-pregnant C21 mice. Transgenic founders were
detected by Southern blot analysis of BamHI digested genomic DNA using a
32P-labeled 980 bp murine VEGF cDNA as the probe. Genomic tail DNA also
was subjected to polymerase chain reaction using two primers specific for
human growth hormone sequences contained in the expression vector; 59-
CTCACCTAGCTGCAATGG-39 and 59-AAGGCACTGCCCTCTTGAA-
GC-39. Initial denaturation at 94°C for 4 min was followed by 35 cycles at
94°C for 30 s, 55°C for 30 s, and 72°C for 30 s, followed by final extension
at 72°C for 5 min. Transgenic lines were established on the FVB genetic
background.
In situ hybridization In situ hybridization of paraffin and frozen sections,
obtained from four wild-type and four transgenic mice for each time point,
was performed as described earlier (Detmar et al, 1994) using pGEM or
pBluescript II plasmids containing mouse VEGF, VEGFR-1, or VEGFR-2
cDNA fragments. In situ hybridizations were performed on abdominal, dorsal,
and tail skin with comparable results. VEGFR-1 and 22 clones were a kind
gift from Clive Wood (Genetics Institute, Cambridge, MA). The flk-1 and flt-
1 sequences were isolated by polymerase chain reaction from a mouse fetal
thymus cDNA library (Finnerty et al, 1993). The murine flk-1 transcription
template was a 392 bp fragment encompassing amino acids 1–130 (nucleotides
268–660 of the flk-1 sequence described previously; Matthews et al, 1991),
cloned into pGEM-T (Promega, Madison, WI). The sequence for murine flt-
1 was obtained by degenerate polymerase chain reaction cloning of kinase
domains that resulted in a 640 bp cDNA fragment encoding the insert region
from amino acid 832–1045 of a sequence described previously (Finnerty et al,
1993). The VEGFR-3 probe was kindly provided by Dr. Kari Alitalo and has
been described elsewhere (Jeltsch et al, 1997). Transcription reactions were
carried out using a Riboprobe Gemini II kit (Promega) in the presence of (α-35S)
UTP. Anti-sense (and control sense) probes were evaluated on alternate sections.
Immunohistochemistry For immunohistochemistry, 6 µm cryostat sections
of ear, abdominal, or dorsal skin obtained from four wild-type and four
transgenic mice were stained with anti-mouse platelet-endothelial cell adhesion
molecule-1 (PECAM-1; CD31), anti-mouse intercellular adhesion molecule-1
(ICAM-1; CD54), anti-mouse E-selectin, P-selectin, L-selectin, anti-mouse
CD3, CD4, CD8, CD 11a, CD11b, CD45, CD 49d (all from Pharmingen,
San Diego, CA), anti-mouse collagen type IV, and anti-desmoplakin I/II
(Biodesign International, Kenneburk, ME), and affinity purified rabbit anti-
mouse collagen XVIII (Rehn and Pihlajaniemi, 1994; kindly provided by Dr.
Marko Rehn), using the Vectastain ABC kit (Vector Laboratories, Burlingame,
CA). Rat IgG1 (R59–40), rat IgG2a (R35–95), or hamster IgG (Ha4/8; all
purchased from Pharmingen) were used as isotype matched negative controls
in monoclonal antibody staining, and normal rabbit serum was used as control
for polyclonal rabbit sera. For quantitation of microvascular densities in the
skin, abdominal skin samples were obtained after CO2 euthanasia from six
transgenic and six wild-type control mice each at 3 d, 11 d, 3 wk, and 6 wk
after birth. Five micrometer paraffin sections were stained for CD31, and the
number of vascular profiles per high-power field (3100 objective) was deter-
mined in the areas immediately below the epidermal–dermal basement mem-
brane zone. At least five random fields per section were evaluated, and data
were evaluated using the paired Student’s t test. Three micrometer plastic
sections were stained for chloroacetate-esterase reactivity (n 5 6) using naphthol-
AS-D-chloroacetate as substrate and 1% methyl green as counterstain. Mast cell
staining was confirmed by methylene blue and Giemsa staining.
Intravital fluorescence microscopy Twenty-four day old wild-type or
transgenic mice (n 5 6 for each group) were injected intravenously with 50 µl
fluoroscein isothiocyanate-labeled dextran (MW, 2000000; Sigma; 10 mg per
ml), and video recording of ear skin perfusion was performed as described
previously (Fukumura et al, 1995). Mice were also injected with 20 µl
Rhodamin-6G (Molecular Probes, Eugene, OR; 50 mg per ml) to visualize
peripheral blood leukocytes (Fukumura et al, 1995). In additional experiments,
24 d old mice (n 5 3 for each group) were injected intraperitoneously with
the following antibodies (150 µg each), either alone or in different combinations
(Fig 6): blocking antibodies against E-selectin (clone 10E9.6), P-selectin (clone
RB.40.34), ICAM-1 (clone 3E2), VCAM-1 (clone 429), L-selectin (clone
MEL-14), lymphocyte function-associated antigen-1 (CD11a; clone M17/4),
or VLA-4 (CD49d; clones R1–1 and 9C10; all purchased from Pharmingen)
3 h prior to examination. For fluorescence microlymphangiography, 5–10 µl
of fluoroscein isothiocyanate-dextran (25 mg per ml) were injected intradermally
into the tail skin (n 5 3 for each group), and fluorescence micrographs were
recorded 40–60 min after injection (Leu et al, 1994). The capillary tortuosity
index was calculated by dividing 100 by the average length (µm) of capillaries
without branching; a minimum of 500 branches was evaluated in each animal.
The rolling count was calculated as 100 3 number of rolling leukocytes/total
leukocyte flux and adhesion density was calculated as the number of adherent
leukocytes per mm2 vascular surface of postcapillary venules as described
(Fukumura et al, 1995).
RESULTS
The aim of this study was to characterize the biologic consequences
of chronic VEGF overexpression in the epidermis of transgenic mice,
using a keratin 14 promoter expression cassette containing the mouse
VEGF164 gene to target VEGF expression selectively to basal epidermal
keratinocytes. Southern blot analysis of genomic DNA revealed trans-
gene incorporation in nine of 30 mice with copy numbers between
three and µ20 (data not shown). Whereas one of these transgenic
mice died and four did not transmit the transgene, four founders with
8–10 transgene copies in their genome transmitted the transgene to
their offspring with a Mendelian inheritance pattern.
Increased expression of VEGF and its receptors in transgenic
mice Targeted expression of the K14-VEGF transgene was confirmed
by in situ hybridization, demonstrating selectively increased VEGF
expression in the basal keratinocyte layer of the epidermis and in the
outer root sheath keratinocytes of hair follicles that also express keratin
14 (Fig 2A–F). Within the upper dermis and surrounding hair follicles,
microvessels expressed highly increased levels of VEGFR-2 mRNA
(Fig 2G–J) and moderately increased levels of VEGFR-1 mRNA (Fig
2K, L). No VEGFR-1 mRNA expression was detectable in wild-type
skin (not shown). In contrast, expression of VEGFR-3 (Flt-4) appeared
unchanged (data not shown). These findings suggest a positive feedback
mechanism, resulting in selective induction of the two high-affinity,
endothelial cell VEGF receptors by keratinocyte-derived VEGF in vivo.
Increased density of blood microvessels in the dermis of trans-
genic mice VEGF transgenic mice were characterized by visibly
increased skin vascularization (Fig 3A). Immunohistochemical staining
for PECAM-1, an endothelial junction molecule (Fig 3B, C) (Dejana
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Figure 2. Induced overexpression of VEGF and VEGFR-2 in the
abdominal skin of K14-VEGF transgenic mice. In situ hybridization of
transgenic skin with mouse VEGF anti-sense (A, B) and sense (C, D) probes
demonstrates strong VEGF mRNA expression in basal epidermal keratinocytes
and in follicular keratinocytes. Parts (E) and (F) show only weak VEGF mRNA
expression in the skin of a wild-type littermate control. Hybridization with
mouse VEGFR-2 anti-sense probe demonstrates increased VEGFR-2 mRNA
expression in dermal microvessels (arrows) in transgenic skin (G, H), as compared
with wild-type skin (I, J). Weak VEGFR-1 mRNA expression in dermal
microvessels (arrows) in transgenic skin (K, L). No VEGFR-1 expression was
detected in wild-type skin (not shown). Bright-field (A, C, E, G, I, K) and
dark-field (B, D, F, H, J, L) microscopy. Scale bar: 25 µm.
et al, 1995), and for collagen types IV and XVIII revealed an increased
number of dermal microvessels within transgenic skin (Fig 3F, G and
data not shown). Morphometric analysis of microvascular profiles per
area unit, using paraffin sections stained for CD31, showed that
microvascular density in wild-type controls was highest during the
neonatal period (Fig 4), and was substantially lower after 3 and 6 wk.
These findings corresponded to the degree of visible skin vascularization.
VEGF transgenic mice were characterized by highly increased numbers
of microvessels per high power microscope field in the abdominal skin
of 3 d old mice (158.3% versus control; p , 0.01; n 5 6) (Fig 4). In
11 d old, 3 wk old, and 6 wk old mice, the increase was less dramatic
(130.2–31.3% versus control; p , 0.05; n 5 6), due to the diminished
expression of the transgene construct in the epidermis of older animals
(Vassar et al, 1989; data not shown). Comparable results were obtained
in dorsal and ear skin. The induced dermal microvessels in VEGF
transgenic mice were not stained by monoclonal antibodies against
desmoplakin I and II (data not shown) expressed by lymphatic, but
not by blood vascular endothelial cells (Schmelz et al, 1994). This
indicated that the induced dermal microvasculature was of blood vessel
rather than lymphatic origin.
Increased density of mast cells in the dermis of transgenic
mice Angiogenesis and increased mast cell localization to sites of
newly forming microvasculature are often associated (Meininger and
Zetter, 1992). When Epon sections of skin of VEGF transgenic mice
were stained for chloroacetate esterase activity (Fig 3D, E) or were
Giemsa stained, a significantly increased density of dermal mast cells
was detected (135.2% versus wild-type littermates, p , 0.05, n 5 6).
These results suggest a role of VEGF in mast cell recruitment to sites
of angiogenesis in vivo. In contrast, skin-infiltrating leukocytes were not
increased in VEGF transgenic mice, as assessed by immunohistochemical
staining for CD3, CD4, CD8, and CD45 expressed by lymphocytes
and CD11b (αM-integrin) expressed by granulocytes and macrophages.
Intravital characterization of skin microvessels To functionally
characterize the induced dermal blood vessels in VEGF transgenic
mice, intravital microscopy of ear skin was performed after intravenous
injection of fluorescently labeled dextran (Fukumura et al, 1995).
Diameter, red blood cell velocity, and shear rate of postcapillary venules
were similar in VEGF transgenic and wild-type mice (Fig 5G, H);
however, in accordance with the data obtained by morphometric
analysis of CD31 stained skin sections, the microvascular density was
significantly increased in the skin of 3 wk old transgenic mice (120.1%
versus control) (Fig 5A, B, I). These capillaries had a highly increased
tortuosity index (169.0%), corresponding to a decreased average
capillary length without branching (Fig 5J). In addition, capillaries in
VEGF transgenic ear skin were hyperpermeable, as evidenced by early
leakage of fluoroscein isothiocyanate-dextran into the perivascular
space (Fig 5B and data not shown). In contrast, microlymphangiography
demonstrated normal numbers and diameters of lymphatic vessels in
transgenic skin (Fig 5E, F).
Enhanced leukocyte rolling and adhesion in postcapillary
venules in transgenic skin Postcapillary venules in VEGF transgenic
ear skin showed a significantly increased proportion of rolling leukocytes
(47.9% versus 15.6% in wild-type skin, p , 0.005) (Fig 5K) and, even
more prominent, an enhanced density of adherent leukocytes (251.9
versus 61.3 cells per mm2, p , 0.005) (Fig 5C, D, L). The enhanced
leukocyte rolling and adhesion was not due to increased numbers of
circulating leukocytes, as white blood cells counts were comparable in
wild-type and transgenic mice. Blocking antibodies against E- and P-
selectin brought the proportion of rolling and adherent leukocytes
back down to levels seen in wild-type mice (Fig 6A). In contrast,
an anti-ICAM-1/lymphocyte function-associated antigen-1 antibody
combination had no effect on leukocyte adhesion; however, no
pronounced alterations of endothelial cell expression levels of E- or
P-selectin were detected within the skin of VEGF transgenic mice by
immunohistochemical staining (data not shown). Leukocyte adhesion
in transgenic mouse skin was potently inhibited by antibody combina-
tions of anti-VCAM-1/VLA-4 and of anti-VCAM-1/ICAM-1 (Fig 6).
This suggested that the increased rolling and adhesion of peripheral
blood leukocytes in postcapillary venules of VEGF transgenic mice
resulted from specific cell adhesion molecule interactions.
DISCUSSION
Previously, we identified VEGF as a major keratinocyte-derived
mitogen for dermal microvascular endothelial cells (Detmar et al, 1995)
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Figure 3. Increased vascularization in the skin of K14-VEGF transgenic mice. (A) Three week old male transgenic mouse and wild-type littermate. Note
the increased vascularization of transgenic skin, most visible in the area of the inner surface of the ear. (B, C) Staining of frozen sections of wild-type and transgenic
abdominal skin, respectively, with anti-mouse PECAM-1 (CD 31). Chloroacetate-esterase staining of 3 µm plastic sections of wild-type (D) and transgenic (E)
skin. Mast cells are visualized by purple granules. (F, G) Anti-mouse collagen type IV; (H, I) anti-mouse ICAM-1 (CD 54) in wild-type (F, H) and transgenic (G,
I) skin. Scale bars: (B, C) 25 µm; (D, E) 100 µm; (F–I) 50 µm.
Figure 4. Increased density of microvessels underlying the epidermal–
dermal basement membrane in the abdominal skin of VEGF transgenic
mice (black bars), as compared with wild-type controls (white bars).
Microvascular density was measured by the average number of microvascular
profiles per high-power field. Mean 6 SD (n 5 6 for each group).
*p , 0.05; **p , 0.01.
with increased expression in psoriasis and other inflammatory diseases
characterized by tortuous, hyperpermeable microvessels and increased
inflammatory infiltration (Detmar et al, 1994; Brown et al, 1995a, b).
To characterize the biologic importance of VEGF for skin angiogenesis
in vivo, we generated a transgene construct to overexpress VEGF
selectively in the epidermis of transgenic mice, using a keratin 14
promoter expression cassette that reliably led to transgene expression
in basal epidermal keratinocytes. Results of this study provide evidence
that selective overexpression of VEGF in mouse epidermis was sufficient
to induce an increased number of dermal blood microvessels, as
demonstrated by morphometric analysis of skin samples stained for the
endothelial cell junction molecule PECAM-1 (Dejana et al, 1995). In
accordance with our findings, increased new blood vessel formation
was recently reported when VEGF was expressed under control of a
bovine rhodopsin promoter, targeting transgene expression to the retina
(Okamoto et al, 1997). The increase in microvascular density was age
dependent and was most prominent in the early postnatal period with
a 58.3% increase of microvascular density in the upper dermis of
K14/VEGF transgenic mice. At later time points, the increase in
microvascular density was less pronounced, though still statistically
significant, caused by a diminished expression level of the K14/VEGF
construct with increasing age of the animals. In vivo fluorescence
angiography of ear skin after intravenous injection of fluoresceinated
high-molecular weight dextran confirmed an increased number of
skin capillaries in transgenic mice. These vessels were tortuous and
hyperpermeable, characteristic features of abnormal microvessels in
psoriasis (Braverman and Sibley, 1982). Thus, these findings support
our hypothesis that, in psoriatic lesions, keratinocyte-derived VEGF is
able to penetrate the epidermal–dermal basement membrane barrier to
exert its biologic effects on target endothelial cells in the upper dermis
(Detmar, 1996).
In K14/VEGF transgenic mice, the expression of the VEGF receptor
flk-1 (VEGFR-2) was highly increased in dermal microvessels in the
vicinity of VEGF overexpressing keratinocytes, whereas the expression
of flt-1 (VEGFR-1) was only moderately induced. These findings are
comparable with the results of our previous in situ hybridization studies
in psoriasis and other inflammatory skin diseases (Detmar et al, 1994;
Brown et al, 1995a, b) that are characterized by epidermal VEGF
overexpression, strong endothelial cell expression of VEGFR-2, and
moderate expression of VEGFR-1. They also suggest a positive
feedback mechanism by which VEGF may upregulate its receptors on
endothelial cells in vivo. This concept is supported by a recent
developmental study using a retroviral vector to overexpress VEGF in
the avian limb, resulting in increased endothelial expression of VEGF
receptors during early embryogenesis (Flamme et al, 1995).
The induced dermal microvessels in VEGF transgenic mice were
stained by an antibody against collagen XVIII that has been suggested
as a specific marker for blood vessel endothelial cells (Rehn and
Pihlajaniemi, 1994). In contrast, no staining was observed with mono-
clonal antibodies against desmoplakin I and II that have been reported
to be selectively expressed by lymphatic endothelial cells (Schmelz
et al, 1994). Moreover, in vivo microlymphangiography after intradermal
injection of fluoroscein isothiocyanate-labeled high molecular weight
dextran, demonstrated normal numbers and diameters of lymphatic
vessels in transgenic skin. Taken together, these findings indicate that
the VEGF-induced dermal microvasculature is of blood vessel rather
than lymphatic origin, and that VEGF acts as a selective angiogenesis
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Figure 5. Intravital analysis of microcirculation, leukocyte rolling and
adhesion, and lymphatic vascularization in VEGF transgenic skin.
Increased numbers of tortuous and hyperpermeable microvessels in transgenic
ear skin (B) as compared with littermate controls (A). After injection of
Rhodamin-6G, increased numbers of leukocytes adherent to postcapillary
venules were detected in transgenic mouse ear skin (D; arrows) as compared
with controls (C). Parts (E) and (F) demonstrate similar numbers and diameters
of lymphatic vessels in wild-type and VEGF transgenic tail skin. No significant
differences of red blood cell velocity (G) and shear rate (H) were detected
between wild-type and transgenic postcapillary venules; however, transgenic
skin showed a 20.1% increase in microvascular density (I), a 69.0% increase in
microvascular tortuosity (J), a 3-fold increase in leukocyte rolling (K), and a
4.1-fold increase in leukocyte adhesion to the wall of postcapillary venules (L).
Scale bars: (A, B) 500 µm; (C, D) 250 µm; (E, F) 350 µm.
factor for blood vessels in the skin. In contrast, a closely related new
member of the VEGF family of growth factors, VEGF-C, did not
induce blood microvessels, but caused lymphatic proliferation and
vessel enlargement when selectively overexpressed in the epidermis of
transgenic mice, using a keratin 14 promoter construct (Jeltsch et al,
1997). Thus, closely related angiogenesis factors exert clearly distinct
effects on the vascular system.
Hyperpermeability of microvessels precedes and accompanies angio-
genesis and vascular remodeling observed in inflammatory and neo-
plastic skin diseases, resulting in leakage of plasma proteins including
clotting factors such as fibrinogen and prothrombin (for review, see
Dvorak et al, 1995). Extravasated plasma proteins activate the extrinsic
coagulation system, leading to the generation of thrombin and cleavage
of fibrinogen to fibrin that is readily cross-linked by activated factor
XIIIa. Cross-linked fibrin as well as other RGD-containing extravasated
Figure 6. Specific inhibition of VEGF-induced leukocyte rolling and
adhesion by blocking antibodies to adhesion molecules. Mice were
injected with 150 µg of each of the respective blocking antibodies or with
equivalent amounts of isotype control antibodies 2 h prior to injection of
rhodamin-6G. Data for leukocyte rolling (A) and adhesion (B) are given as the
percentage of wild-type control and represent means of 2–3 experiments.
plasma proteins such as fibronectin and vitronectin provide a provisional
matrix supporting endothelial cell migration. Our findings of increased
microvascular permeability in the skin of VEGF transgenic mice,
together with the observed increase in microvascular density, further
support the hypothesis that VEGF promotes angiogenesis and vascular
remodeling in skin diseases such as psoriasis and squamous cell
carcinomas through both induction of vascular leakiness and direct
stimulation of endothelial cell migration and proliferation (Detmar,
1996; Senger et al, 1996), and suggest a significant role of vascular
hyperpermeability in the clinical course of these diseases.
In addition to the observed vascular changes, VEGF transgenic mice
showed an approximately 35% increase in mast cell densities in the
upper dermis. Although this increase was rather moderate, these
findings are in agreement with observations of increased mast cell
localization to sites of angiogenesis (Meininger and Zetter, 1992). In
particular, psoriasis and murine psoriasiform skin lesions (Scho¨n et al,
1997) are characterized by both increased epidermal VEGF expression
(Detmar et al, 1994) and enhanced dermal mast cell numbers (Kreuter
et al, 1978). At present, a mechanistic explanation for the mast
accumulation in VEGF transgenic mice remains to be established.
Whereas we were unable to detect expression of VEGFR-1 or
VEGFR-2 by mast cells in the skin, a direct chemotactic effect of
VEGF on mast cells in vitro has been recently reported (Gruber
et al, 1995). Alternatively, VEGF released from transgenic epidermal
keratinocytes might indirectly induce mast cell accumulation through
induction of increased microvascular density in the skin that may lead
to increased release of mast cell recruiting factors by endothelial cells.
It has been shown that injection of stem cell factor into mouse skin
potently induced mast cell hyperplasia (Tsai et al, 1991), and that
overexpression of nerve growth factor in the skin of transgenic mice
led to increased dermal mast cell density (Getchell et al, 1995). Both
stem cell factor (Aye et al, 1992; Meininger et al, 1995) and nerve
growth factor (M. Detmar and C. Pincelli, unpublished data) are
produced by endothelial cells, and it remains to be explored in future
studies whether VEGF might regulate their expression in dermal
microvascular endothelial cells. Notwithstanding our incomplete know-
ledge of the molecular mechanisms involved, our results for the first
time demonstrate a role of VEGF in mast cell recruitment to sites of
angiogenesis in vivo.
VEGF transgenic mice were also characterized by dramatically
increased leukocyte rolling (.3-fold) and adhesion (.4-fold) in
postcapillary venules in ear skin. These findings were not due to
increased numbers of circulating leukocytes, as white blood cell counts
were comparable in wild-type and transgenic mice. Moreover, blood
flow and shear rate were identical in postcapillary venules of wild-
type and transgenic skin, suggesting that specific adhesion molecule
interactions were responsible for the observed increase in leukocyte
adhesion and rolling in transgenic skin. Indeed, in vivo blocking studies
using intraperitoneal application of various combinations of blocking
antibodies to adhesion molecules demonstrated that the increased
number of rolling and adherent leukocytes was normalized after
injection of an anti-E- and P-selectin antibody combination. We were
unable, however, to detect pronounced alterations of E- or P-
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selectin expression within the skin of VEGF transgenic mice by
immunohistochemical staining. This may reflect the low sensitivity of
the immunohistochemical approach, or may reflect only subtle differ-
ences in selectin expression that are already sufficient to lead to biologic
effects. This is supported by the only moderate increase of in vitro E-
selectin expression in VEGF treated human umbilical vein endothelial
cells reported recently (Melder et al, 1996). Combinations of anti-
VCAM-1/VLA-4 and VCAM-1/ICAM-1 antibodies potently down-
regulated leukocyte adhesion. These findings are in accordance with
the previously reported in vitro effects of VEGF on the expression of
cell adhesion molecules in cultured human umbilical vein endothelial
cells (Melder et al, 1996).
It is of interest that the observed increases in leukocyte rolling and
adhesion in postcapillary venules in transgenic ear skin were not
associated with increased numbers of infiltrating leukocytes in the
dermis or epidermis in mouse ears. Immunohistochemical staining for
CD3, CD4, CD8, CD11a, or CD49d did not reveal an increased
number of infiltrating leukocytes in the dermis of transgenic mice.
Thus, it appears that VEGF plays an important role in early steps of
leukocyte recruitment to sites of angiogenesis, but is not sufficient to
induce the entire cascade of leukocyte localization seen in inflammatory
conditions.
In summary, targeted overexpression of VEGF in epidermal ker-
atinocytes led to a significantly increased density of hyperpermeable
and tortuous skin microvessels. Whereas VEGF has been widely
regarded as an endothelial cell specific growth factor, VEGF transgenic
mice also demonstrated increased mast cell numbers and enhanced
leukocyte rolling and adhesion to postcapillary venules, characteristic
features of healing wounds and chronic inflammatory skin diseases
such as psoriasis. Thus, our findings suggest much broader, previously
unsuspected biologic functions of VEGF, providing a molecular link
between angiogenesis, mast cell accumulation, and enhanced leukocyte
adhesion to postcapillary venules in chronic inflammation.
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